Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes

Acta Diabetologica

Volumn 51, Issue 5, 2014, Pages 865-873

  Bi, Yan ^a   Zhang, Bing ^a   Xu, Wen ^b   Yang, Huijie ^a   Feng, Wenhuan ^a   Li, Cuiliu ^a   Tong, Guoyu ^a   Li, Ming ^a   Wang, Xin ^a   Shen, Shanmei ^a   Zhu, Bin ^a   Weng, Jianping ^b,c   Zhu, Dalong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c Environmental Pollution Control and Remediation Technology   (China)

Author keywords

Body fat; Exenatide; Insulin; Liver fat content; Pioglitazone; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; EXENDIN 4; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO; LOW DENSITY LIPOPROTEIN; PIOGLITAZONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; FAT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PEPTIDE; VENOM;

ADIPOSE TISSUE; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY FAT DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MECHANISM; FAT CONTENT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; INTRAHEPATIC FAT; LIPID ANALYSIS; LIVER FAT CONTENT; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; LIVER; METABOLISM; MULTICENTER STUDY;

ADIPONECTIN; BLOOD GLUCOSE; BODY FAT DISTRIBUTION; DIABETES MELLITUS, TYPE 2; FATS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; MALE; PEPTIDES; THIAZOLIDINEDIONES; VENOMS;

EID: 84919489727     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0638-3     Document Type: Article

References (37)

1. McGarry JD (2001) Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51:7–18
2. Unger RH (2008) Reinventing type 2 diabetes: pathogenesis, treatment, and prevention. JAMA 299:1185–1187
3. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL (2012) Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344:d7771
4. Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, Düring M, Zdravkovic M, Strauss BJ, Garber AJ (2009) LEAD-2 and LEAD-3 study groups weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 11:1163–1172
5. Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ (2012) Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One 7:e50117
6. Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M (2011) Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring) 19:2310–2315
7. Lindberg M, Astrup A (2007) The role of glitazones in management of type 2 diabetes. A dream or a nightmare? Obes Rev 8:381–384
8. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA (2003) Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52:1364–1370
9. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H (2008) Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371:1753–1760
10. Hu Y, Li L, Xu Y, Yu T, Tong G, Huang H, Bi Y, Weng J, Zhu D (2011) Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission. Diabetes Care 34:1848–1853
11. Juurinen L, Tiikkainen M, Häkkinen AM, Hakkarainen A, Yki-Järvinen H (2007) Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 292:E829–E835
12. Shah PK, Mudaliar S, Chang AR, Aroda V, Andre M, Burke P, Henry RR (2011) Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes. Diabetes Obes Metab 13:505–510
13. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553
14. Xu W, Bi Y, Sun Z, Li J, Guo L, Yang T, Wu G, Shi L, Feng Z, Qiu L, Li Q, Guo X, Luo Z, Lu J, Shan Z, Yang W, Ji Q, Yan L, Li H, Yu X, Li S, Zhou Z, Lv X, Liang Z, Lin S, Zeng L, Yan J, Ji L, Weng J (2014) Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study). J Intern Med Jul 16, Epub ahead of print
15. Bi Y, Zeng LY, Zhu DL, Yan J, Zhang Y, Tong G, Mu P, Shen S, Hu Y, Yu Q, Liang H, Weng J (2012) Association of β-cell function and insulin sensitivity with fasting and 2 h plasma glucose in a large Chinese population. Diabetes Obes Metab 14:174–180
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419
17. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470
18. Thomas EL, Hamilton G, Patel N, O’Dwyer R, Doré CJ, Goldin RD, Bell JD, Taylor-Robinson SD (2005) Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 54:122–127
19. Liska D, Dufour S, Zern TL, Taksali S, Calí AM, Dziura J, Shulman GI, Pierpont BM, Caprio S (2007) Interethnic differences in muscle, liver, and abdominal fat partitioning in obese adolescents. PLoS One 2:e569
20. Hwang JH, Stein DT, Barzilai N, Cui MH, Tonelli J, Kishore P, Hawkins M (2007) Increased intrahepatic triglyceride is associated with peripheral insulin resistance: in vivo MR imaging and spectroscopy studies. Am J Physiol Endocrinol Metab 293:E1663–E1669
21. Porepa L, Ray JG, Sanchez-Romeu P, Booth GL (2010) Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ 182:E526–E531
22. Musso G, Cassader M, Rosina F, Gambino R (2012) Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55:885–904
23. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI (2005) Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54:603–608
24. Kenny PR, Brady DE, Torres DM, Ragozzino L, Chalasani N, Harrison SA (2010) Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol 105:2707–2709
25. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R (2011) Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 54:2506–2514
26. Asrih M, Jornayvaz F (2013) Inflammation as a link between nonalcoholic fatty liver disease and insulin resistance. J Endocrinol 218:R25–R36
27. Daniele G, Guardado Mendoza R, Winnier D, Fiorentino TV, Pengou Z, Cornell J, Andreozzi F, Jenkinson C, Cersosimo E, Federici M, Tripathy D, Folli F (2014) The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 51:123–131
28. Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S, Fanti P, Jenkinson C, Andreozzi F, Federici M, Gastaldelli A, Defronzo RA, Folli F (2013) Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia 56:2153–2163
29. Lesmana CR, Hasan I, Budihusodo U, Gani RA, Krisnuhoni E, Akbar N, Lesmana LA (2009) Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis. J Did Dis 10:201–206
30. Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, Hirschhorn JN, O’Donnell CJ, Fox CS (2010) Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham heart study. Hepatology 51:1979–1987
31. Fernández-Miranda C, Pérez-Carreras M, Colina F, López-Alonso G, Vargas C, Solís-Herruzo JA (2008) A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 40:200–205
32. Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, Papa G, Rabuazzo AM, Purrello F (2008) Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 40:194–199
33. Deurenberg P, Yap M, van Staveren WA (1998) Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes Relat Metab Disord 22:1164–1171
34. Chiu KC, Cohan P, Lee NP, Chuang LM (2000) Insulin sensitivity differs among ethnic groups with a compensatory response in beta-cell function. Diabetes Care 23:1353–1358
35. Ma RC, Chan JC (2013) Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann NY Acad Sci 1281:64–91
36. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J (2010) China National Diabetes and Metabolic Disorders study group prevalence of diabetes among men and women in China. N Engl J Med 362:1090–1101
37. Bazzocchi A, Diano D, Ponti F, Salizzoni E, Albisinni U, Marchesini G, Battista G (2014) A 360-degree overview of body composition in healthy people: relationships among anthropometry, ultrasonography, and dual-energy X-ray absorptiometry. Nutrition 30:696–701